The aim of the present study was to analyze the biologic characteristics and clinical significance of CEP17 gain and explore the impact on luminal B molecular subclassification combined with estrogen receptor (ER) and progesterone receptor (PR) expression in a large population of breast cancer patients. Here, PGR is linked to breast carcinoma.